Foghorn Therapeutics (FHTX) Return on Equity (2020 - 2025)
Historic Return on Equity for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 0.9%.
- Foghorn Therapeutics' Return on Equity fell 33800.0% to 0.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9%, marking a year-over-year decrease of 33800.0%. This contributed to the annual value of 1.41% for FY2024, which is 11400.0% down from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Return on Equity is 0.9%, which was down 33800.0% from 1.12% recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Return on Equity ranged from a high of 9.19% in Q1 2023 and a low of 8.91% during Q4 2022
- Moreover, its 5-year median value for Return on Equity was 1.06% (2024), whereas its average is 0.52%.
- Per our database at Business Quant, Foghorn Therapeutics' Return on Equity skyrocketed by 104400bps in 2023 and then plummeted by -81300bps in 2024.
- Foghorn Therapeutics' Return on Equity (Quarter) stood at 1.15% in 2021, then crashed by -672bps to 8.91% in 2022, then skyrocketed by 116bps to 1.46% in 2023, then surged by 60bps to 2.35% in 2024, then plummeted by -62bps to 0.9% in 2025.
- Its Return on Equity was 0.9% in Q3 2025, compared to 1.12% in Q2 2025 and 1.53% in Q1 2025.